HHT is a protein translation inhibitor and induces apoptosis in AML cells with Mcl-1 downregulation, and it is approved for treatment of chronic myeloid leukemia resistant to BCR-ABL inhibitors [39, 40]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.